This is in agreement with several studies, demonstrating that NLRP3 activation promoted tumor development in experimental models (41–47) and is associated with susceptibility to melanoma (48) and with poor survival in patients with advanced colorectal cancer (49) or development of various hematologic malignancies (47, 50). The gene discussed is NLRP3; the disease is hematologic disorder.